Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 2—February 2012

Declining Guillain-Barré Syndrome after Campylobacteriosis Control, New Zealand, 1988–2010

Michael G. BakerComments to Author , Amanda Kvalsvig, Jane Zhang, Rob Lake, Ann Sears, and Nick Wilson
Author affiliations: University of Otago, Wellington, New Zealand (M.G. Baker, A. Kvalsvig, J. Zhang, A. Sears, N. Wilson); Institute of Environmental Science and Research, Christchurch, New Zealand (R. Lake)

Main Article

Table 1

Incidence of campylobacteriosis and GBS before and after intervention to reduce Campylobacter spp. in poultry, New Zealand 2002–2010*

Incident condition Before intervention, 2002–2006
After intervention, 2008–2010†
Total no. Average/year Rate‡ Total no. Average/year Rate‡ Rate ratio (95% CI) p value
Campylobacteriosis notifications§ 69,207 13,841 339.4 21,217 7,072 163.8 0.48 (0.48–0.49) <0.0001
Campylobacteriosis hospitalizations¶ 4,669 934 23.2 1,603 534 12.2 0.53 (0.51–0.54) <0.0001
GBS hospitalizations¶ 513 103 2.6 290 97 2.2 0.87 (0.81–0.93) 0.0496

*GBS, Guillain-Barré syndrome.
†Excludes 2007, which was a transitional year.
‡Annual no. cases/100,000 person-years at risk. Denominator populations based on mean population estimates published by Statistics New Zealand ( Campylobacteriosis and Guillan-Barré syndrome hospitalizations used age-standardized rates based on the age structure of the New Zealand 2006 Census of Population and Dwellings (
§Published campylobacteriosis notification data (9).
¶Hospitalization data from New Zealand Ministry of Health.

Main Article

  1. van Doorn  PA, Ruts  L, Jacobs  BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:93950. DOIPubMedGoogle Scholar
  2. McGrogan  A, Madle  GC, Seaman  HE, de Vries  CS. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology. 2009;32:15063. DOIPubMedGoogle Scholar
  3. Jacobs  BC, van Belkum  A, Endtz  HP. Guillain-Barré syndrome and Campylobacter infection. In: Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter, 3rd ed. Washington: ASM Press; 2008. p. 245–62.
  4. Nachamkin  I, Allos  BM, Ho  T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998;11:55567.PubMedGoogle Scholar
  5. Baker  M, Wilson  N, Ikram  R, Chambers  S, Shoemack  P, Cook  G. Regulation of chicken contamination is urgently needed to control New Zealand's serious campylobacteriosis epidemic. N Z Med J. 2006;119:U2264.PubMedGoogle Scholar
  6. Baker  MG, Sneyd  E, Wilson  N. Is the major increase in notified campylobacteriosis in New Zealand real? Epidemiol Infect. 2007;135:16370. DOIPubMedGoogle Scholar
  7. Sears  A, Baker  MG, Wilson  N, Marshall  J, Muellner  P, Campbell  DM, Marked campylobacteriosis decline after interventions aimed at poultry, New Zealand. Emerg Infect Dis. 2011;17:100715. DOIPubMedGoogle Scholar
  8. Baker  MG, Sears  A, Wilson  N, French  N, Marshall  J, Muellner  P, Keep the focus on contaminated poultry to further curtail New Zealand’s campylobacteriosis epidemic. N Z Med J. 2011;124:1359.PubMedGoogle Scholar
  9. Institute of Environmental Science and Research Ltd. Notifiable and other diseases in New Zealand: annual report 2010. Porirua (New Zealand): The Institute; 2011.
  10. McCarthy  N, Giesecke  J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001;153:6104. DOIPubMedGoogle Scholar
  11. Rothman  K, Greenland  S, Lash  T, eds. Modern epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
  12. Poropatich  KO, Walker  CL, Black  RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr. 2010;28:54552. DOIPubMedGoogle Scholar
  13. Black  S, Eskola  J, Siegrist  C, Halsey  N, MacDonald  N, Law  B, Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374:211522. DOIPubMedGoogle Scholar
  14. DeStefano  F, Tokars  J. H1N1 vaccine safety monitoring: beyond background rates. Lancet. 2010;375:11467. DOIPubMedGoogle Scholar
  15. Lake  R, Baker  M, Nichol  C, Garrett  N. Lack of association between long-term illness and infectious intestinal disease in New Zealand. N Z Med J. 2004;117:U893.PubMedGoogle Scholar
  16. Alshekhlee  A, Hussain  Z, Sultan  B, Katirji  B. Guillain-Barré syndrome. Neurology. 2008;70:160813. DOIPubMedGoogle Scholar
  17. Tam  CC, O’Brien  SJ, Petersen  I, Islam  A, Hayward  A, Rodrigues  LC. Guillain-Barré syndrome and preceding infection with Campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE. 2007;2:e344. DOIPubMedGoogle Scholar
  18. Hadden  RD, Gregson  NA. Guillain-Barré syndrome and Campylobacter jejuni infection. Symp Ser Soc Appl Microbiol. 2001;30:145S54S.PubMedGoogle Scholar
  19. Tam  CC, Rodrigues  LC, Viviani  L, Dodds  JP, Evans  MR, Hunter  PR, Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut. 2011 Jun 27; [Epub ahead of print]. PubMedGoogle Scholar
  20. Hall  G, Yohannes  K, Raupach  J, Becker  N, Kirk  M. Estimating community incidence of Salmonella, Campylobacter, and Shiga toxin–producing Escherichia coli infections, Australia. Emerg Infect Dis. 2008;14:16019.PubMedGoogle Scholar
  21. Sejvar  JJ, Baughman  AL, Wise  M, Morgan  OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:12333. DOIPubMedGoogle Scholar
  22. Chiò  A, Cocito  D, Leone  M, Giordana  MT, Mora  G, Mutani  R. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:114650.PubMedGoogle Scholar
  23. Cheng  Q, Jiang  GX, Fredrikson  S, Link  H, De Pedro-Cuesta  J. Incidence of Guillain-Barré syndrome in Sweden 1996. Eur J Neurol. 2000;7:116.PubMedGoogle Scholar
  24. Hadden  RDM, Karch  H, Hartung  H-P, Zielasek  J, Weissbrich  B, Schubert  J, Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001;56:75865.PubMedGoogle Scholar
  25. Van Koningsveld  R, Van Doorn  PA, Schmitz  PIM, Ang  CW, Van der Meche  FGA. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands. Neurology. 2000;54:620.PubMedGoogle Scholar
  26. Lehmann  HC, Hartung  H-P, Kieseier  BC, Hughes  RAC. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10:64351. DOIPubMedGoogle Scholar
  27. Abbi  KK, Rizvi  SM, Sivik  J, Thyagarajan  S, Loughran  T, Drabick  JJ. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature. Leuk Res. 2010;34:e1546. DOIPubMedGoogle Scholar
  28. Kelly  JJ, Karcher  DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005;31:30113. DOIPubMedGoogle Scholar
  29. Zhang  L, Arrington  S, Keung  YK. Guillain-Barré syndrome after transplantation. Leuk Lymphoma. 2008;49:2917. DOIPubMedGoogle Scholar
  30. Baker  MG, Easther  S, Wilson  N. A surveillance sector review applied to infectious diseases at a country level. BMC Public Health. 2010;10:332. DOIPubMedGoogle Scholar
  31. Hughes  RA, Swan  AV, Raphael  JC, Annane  D, van Koningsveld  R, van Doorn  PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:224557. DOIPubMedGoogle Scholar
  32. Bernsen  RA, de Jager  AE, Schmitz  PI, van der Meche  FG. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci. 2002;201:137. DOIPubMedGoogle Scholar
  33. Lake  RJ, Cressey  PJ, Campbell  DM, Oakley  E. Risk ranking for foodborne microbial hazards in New Zealand: burden of disease estimates. Risk Anal. 2010;30:74352. DOIPubMedGoogle Scholar

Main Article

Page created: January 26, 2012
Page updated: January 26, 2012
Page reviewed: January 26, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.